A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma.

The article discusses a randomized trial comparing ibrutinib-R-GDP (IR-GDP) with R-GDP in adults with relapsed and refractory diffuse large B-cell lymphoma. The study found that IR-GDP led to more documented infections without improving overall response compared to R-GDP. The trial was approved by research ethics boards, and after reviewing toxicity and efficacy, the IR-GDP arm was closed prematurely due to futility. The study highlights the importance of biomarker-driven trials and the evolving landscape of therapy for relapsed and refractory DLBCL. [Extracted from the article]